Designation of Natalizumab (TYSABRI) as an Orphan Drug - Biogen Idec Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, is a comprehensive piece of legislation designed to regulate the supply, import, and export of therapeutic goods within the country. The Act addresses a critical gap by ensuring that therapeutic goods available in Australia are safe, of acceptable quality, and properly represented, thereby protecting public health. In 2014, a gazette was issued under this Act to designate natalizumab (TYSABRI) as an orphan drug for the treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years. This designation, made by Dr Anthony Gill, the Delegate of the Secretary for the purposes of the Therapeutic Goods Regulations 1990, recognises the need for specialised treatments for rare diseases and aims to incentivise the development and availability of such therapeutic products for conditions that affect a small number of people. The policy objective behind this designation is to facilitate access to potentially life-saving treatments for children suffering from this debilitating condition, aligning with broader health objectives to enhance the quality of life for patients with rare diseases.

Scope and Application

The Therapeutic Goods Act 1989, as amended and applied through the Therapeutic Goods Regulations 1990, pertains to the regulation of therapeutic goods in Australia. In this context, the Act and its regulations designate specific drugs as orphan drugs, which are intended for the treatment of rare medical conditions. Specifically, the legislation designates natalizumab (TYSABRI) as an orphan drug for the treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years. This designation applies to the concentrated injection solution dose form of the drug and is sponsored by Biogen Idec Australia. The application of this Act is not limited by geography but extends across the Commonwealth of Australia, encompassing all states and territories. The orphan drug designation facilitates incentives for the development of drugs for rare conditions, and it is subject to the overarching provisions of the Therapeutic Goods Act and its regulations, which may be further elaborated or modified through subordinate instruments. Exclusions and exemptions from the scope of the Act would need to be determined in accordance with the specific provisions and any applicable subordinate legislation.

Key Provisions

The Therapeutic Goods Act 1989 (section 16J of the Therapeutic Goods Regulations 1990) designates natalizumab (TYSABRI) as an orphan drug for the treatment of relapsing-remitting multiple sclerosis in children aged between 10 and 17 years. This designation, effective from 1 July 2014, is granted to natalizumab in its concentrated injection solution form, with Biogen Idec Australia identified as the sponsor. This legislative action recognises the specific therapeutic need for natalizumab in this particular demographic, aiming to facilitate its development and availability as a treatment option. The obligations under this Act primarily concern the sponsor, Biogen Idec Australia, who must ensure that natalizumab (TYSABRI) meets all regulatory requirements for safety, quality, and efficacy as specified by the Therapeutic Goods Administration (TGA). This includes providing adequate data to support the orphan drug designation and complying with ongoing reporting and monitoring obligations to maintain the drug's status and market approval. The sponsor must also ensure that the drug is manufactured, stored, and distributed in accordance with the TGA's guidelines. Failure to comply with the obligations and requirements set out in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can lead to significant legal consequences. The Act imposes civil and criminal penalties for non-compliance, which may include fines and imprisonment. Specifically, under the Therapeutic Goods Act 1989, the maximum penalties for contravening the Act can include substantial fines for corporations and imprisonment for individuals responsible for the contravention. These penalties are intended to enforce compliance and ensure the safety and efficacy of therapeutic goods available in Australia.